Enabling The New Age of Oncology Innovation

Payers are not prepared for the cost and uncertainty underlying innovations in cancer treatment. The Breakthrough Oncology Accelerator establishes a new capital source to provide immediate liquidity to the high cost cancer therapy market, ensuring patients receive potentially curative treatments now.

There is a new wave of extraordinary cancer drugs hitting the market. Many have the potential to become game changers but are going to cost between $500 thousand to more than $1MM per therapy. In addition to these drugs, a large portion of the cost is tied up in the services provided by the clinic, given the high complexity of administering the therapies.

Hospitals and large insurers are observing a faster than expected movement of many of these therapies to first-line, yet have no solution for how to finance these drugs and supporting services. This has created a significant backlog of patients in dire need at the nation’s elite cancer clinics.